Multiple Myeloma News

Here are all the latest news articles written by The Beacon's staff.

For news articles about treatments commonly given to myeloma patients, click on these links:
bisphosphonates, KyprolisPomalyst (Imnovid), Revlimid, thalidomide, Velcade, and Zometa.

For news articles about potential new myeloma treatments, click on these links:
ARRY-520 (filanesib), ACY-1215 (ricolinostat), afuresertib (GSK2110183), BT-062, daratumumab, elotuzumab, ixazomib (MLN9708),  marizomib (NPI-0052), MOR202, oprozomib, panobinostat, SAR650984, Treanda (bendamustine), and Zolinza (vorinostat).

For news articles about specific myeloma-related topics, click on these links:
bone disease, kidney failure, MGUS, maintenance therapy, peripheral neuropathysecondary cancer, smoldering multiple myeloma, and stem cell transplants.

[ by | Feb 26, 2015 7:40 pm | 3 Comments ]
Farydak – Questions & Answers About The FDA Approval

The U.S. Food and Drug Administration (FDA) on Monday approved Farydak (panobinostat) for the treatment of multiple myeloma (see related Beacon news).

Since the FDA announced its decision, multiple myeloma patients, care­givers, and health care professionals have been asking a number of important questions about Farydak. This article compiles many of those questions and provides answers to them.

The information in this article is based primarily on the official, FDA-approved prescribing information for Farydak. In addition, The Beacon has received feedback in regard to …

Read the full story »
[ by | Feb 23, 2015 3:30 pm | 13 Comments ]
FDA Approves Farydak (Panobinostat) For The Treatment Of Relapsed Multiple Myeloma

The U.S. Food and Drug Administration (FDA) has approved panobinostat, which will be marketed under the brand name Farydak, for the treatment of relapsed and refractory multiple myeloma.

Specifically, Farydak has been approved for use in combination with Velcade (bortezomib) and dexamethasone (Decadron) in patients with multiple myeloma who have received at least two prior standard therapies.

The two prior therapies must include Velcade and at least one treatment from the immunomodulatory class of drugs, which includes Revlimid (lenalidomide), thalidomide, and Pomalyst …

Read the full story »
[ by | Feb 18, 2015 7:43 pm | 2 Comments ]
FDA Broadens Revlimid's Approved Use To Include Newly Diagnosed Multiple Myeloma

The U.S. Food and Drug Administration (FDA) has ex­panded the of­ficial­ly ap­proved use of Revlimid to include the treat­ment of newly diag­nosed multiple myeloma.

Previously, Revlimid’s approval in the U.S. and elsewhere in the world was for the treat­ment of myeloma patients who have re­ceived at least one prior therapy.

With the expanded U.S. approval, there no longer is any re­striction regard­ing prior therapies in the FDA-approved pre­scrib­ing in­for­ma­tion for Rev­limid (lena­lido­mide).

The new edition of the pre­scrib­ing in­for­ma­tion says simply that “Revlimid in combination with dexa­metha­sone is …

Read the full story »
[ by | Feb 11, 2015 8:25 am | 13 Comments ]
Ixazomib Succeeds In Key Phase 3 Relapsed Multiple Myeloma Trial – Approval Filings Expected Later This Year

Takeda Oncology yesterday announced posi­tive results from a key trial testing the in­ves­ti­ga­tional drug ixazomib in relapsed multiple myeloma patients.

Participants in the large Phase 3 ixazomib trial, known as the TOUR­MA­LINE MM-1 study, received one of two possible treatment regimens. One group was treated with ixazomib, Revlimid (lenalidomide), and dexa­metha­sone (Decadron), while the other group received a placebo (sugar pill), Revlimid, and dexa­metha­sone.

Investigators conducting the trial recently carried out the first planned interim analysis of the study results. Their analysis, Takeda reported …

Read the full story »
[ by | Jan 30, 2015 3:07 pm | 4 Comments ]
The Myeloma Quiz – January 2015

A new year is upon us.  I hope it has started well for everybody, and that all had a great holiday season!

The last few weeks of 2014 were a happening time for the multiple myeloma community. The short span of time witnessed the publication of updated criteria for the diagnosis of multiple myeloma from the Inter­na­tional Myeloma Working Group (IMWG). In addition, the 56th annual meeting of the American Society of Hematology (ASH) took place in San Francisco, with literally hundreds of myeloma-related oral and poster pre­sen­ta­tions.

Therefore, it …

Read the full story »
[ by | Dec 10, 2014 3:12 pm | 3 Comments ]
ASH 2014 Multiple Myeloma Update - Day Two: Education Session And Midday Oral Session

This past Sunday was the second day of the American Society of Hema­tology’s (ASH) annual meeting, which was held in San Francisco.

As on the first day of the meeting, myeloma-related pre­sen­ta­tions once again took place during several sessions throughout the day.

A myeloma-related education session held the first day of the conference was repeated once again on Sunday morning.

While the education session was being held, a separate “scientific sym­po­sium” with two oral pre­sen­ta­tions took place in parallel.  The session focused on a novel immunotherapeutic approach to treating cancer …

Read the full story »